Related Experiment Videos
Phase II evaluation of menogaril in patients with advanced hypernephroma
H J Long1, M D Hauge, T M Therneau
1Mayo Clinic, Rochester, MN 55905.
Abstract:
Fifteen patients with advanced renal cell carcinoma were treated with Menogaril, 200 mg/m2 by one-hour, intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was two months, and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis at the infusion site was seen in 47% of patients. Menogaril as administered in this protocol is ineffective in advanced renal cell carcinoma.
Insights
Menogaril showed no effectiveness in treating advanced renal cell carcinoma. The chemotherapy caused neutropenia and venous irritation, with no objective regressions observed in patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced renal cell carcinoma (RCC) presents a significant therapeutic challenge.
- Novel chemotherapeutic agents are continuously investigated for efficacy in metastatic RCC.
Purpose of the Study:
- To evaluate the efficacy and safety of Menogaril in patients with advanced renal cell carcinoma.
- To determine objective regression rates, time to progression, and overall survival in Menogaril-treated RCC patients.
Main Methods:
- A phase II clinical trial was conducted involving fifteen patients with advanced RCC.
- Patients received Menogaril at a dose of 200 mg/m2 intravenously over one hour every four weeks.
- Adverse events, objective regressions, time to progression, and survival were meticulously monitored.
Main Results:
- No objective regressions were observed in any of the fifteen patients treated.
- The median time to progression was two months, and the median survival was seven months.
- All patients experienced neutropenia; platelet toxicity was minimal. Venous irritation and phlebitis occurred in 47% of patients.
Conclusions:
- Menogaril, administered at 200 mg/m2 every four weeks, demonstrated ineffectiveness in treating advanced renal cell carcinoma.
- The observed toxicity profile, including neutropenia and local infusion site reactions, further supports its lack of clinical utility in this setting.